A Phase 3 interventional study of Tofacitinib and Tofacitinib in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 36 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-10-12.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 21st largest by enrollment, is one of 3 that started in 2014, is one of 11 in phase 3, and was the 25th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Shaikh Zayed Hospital, Lahore · Sites in Pakistan
Ages 50–85
University Hospital, Toulouse · Sites in France
Ages 18–65
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Marie Hudson, MD · Sites in Canada
Ages 18+
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 209 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 170 across the 43 interventional studies. Of the 30 that completed or were terminated, 23 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
152 studies in Arthritis, Rheumatoid by Pfizer: 2 open now, 2 under way, none of them phase 3. Of 149 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 38th largest by enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2014, is one of 18 in phase 3, and was the 115th registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a 12 week study that will evaluate the efficacy and safety of the 11 mg tofacitinib modified release tablet taken once a day in patients with rheumatoid arthritis who continue taking methotrexate. Results for the modified release tablets will be compared to the efficacy and safety of the 5 mg tofacitinib immediate release tablets taken twice a day in patients with rheumatoid arthritis who continue taking methotrexate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Tofacitinib
Drug: Tofacitinib
tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joints count, CRP (milligrams per liter \[mg/L\]) and patient global assessment of disease activity on a 100 millimeter (mm) visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \[less than or equal to\] \<= 3.2 implied low disease activity and greater than (\>) 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) less than (\<) 2.6 implied remission.
Time frame: Baseline, Week 12
Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 12
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (millimeters per hour \[mm/hr\]) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission.
Time frame: Baseline, Week 12
Number of Participants Achieving an American College of Rheumatology 20 Percent [%] (ACR20) Response at Week 12
Participants with 20% improvement in 68-tender and 66-swollen joint counts and 20% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
Time frame: Week 12
Number of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12
Participants with 50% improvement in 68-tender and 66-swollen joint counts and 50% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
Time frame: Week 12
Number of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Week 12
Participants with 70% improvement in 68-tender and 66-swollen joint counts and 70% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
Time frame: Week 12
Number of Participants With DAS Remission (DAS28-4-CRP <2.6) at Week 12
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. Number of participants with DAS remission (DAS28-4-CRP\<2.6) were reported in this outcome measure.
Time frame: Week 12
Number of Participants With DAS Remission (DAS28-4-ESR <2.6) at Week 12
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. Number of participants with DAS remission (DAS28-4-ESR\<2.6) were reported in this outcome measure.
Time frame: Week 12
Number of Participants With Low Disease Activity (DAS28-4-CRP <=3.2) at Week 12
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. Number of participants with low disease activity (DAS28-4-CRP\<=3.2) were reported in this outcome measure.
Time frame: Week 12
Number of Participants With Low Disease Activity (DAS28-4-ESR <=3.2) at Week 12
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. Number of participants with low disease activity (DAS28-4-ESR\<=3.2) were reported in this outcome measure.
Time frame: Week 12
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities over past week. Each activity category consisted of 2-3 items. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
Time frame: Baseline, Week 12
Number of Participants Achieving an Improvement of at Least 0.22 Units in Health Assessment Questionnaire (HAQ Scores) at Week 12
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities over past week. Each activity category consisted of 2-3 items. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities. Number of participants with an improvement of at least 0.22 units in HAQ scores from baseline to Week 12 were reported in this outcome measure.
Time frame: Week 12
Change From Baseline in the Short Form 36 (SF-36) Health Survey Domain Scores at Week 12
SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were aggregated to derive the two component scores (physical component scores \[PCS\], mental component scores \[MCS\]) ranging from 0 (worst) to 100 (best), where higher scores indicated good health condition.
Time frame: Baseline, Week 12
Change From Baseline in the Short Form 36 (SF-36) Health Survey Component Scores at Week 12
SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were aggregated to derive the two component scores PCS and MCS ranging from 0 (worst) to 100 (best), where higher scores indicated good health condition.
Time frame: Baseline, Week 12
Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Scores at Week 12
The FACIT-Fatigue Scale was a participant completed questionnaire consisted of 13 items that assessed fatigue. Each item was scored on a scale of 0 (not at all) to 4 (very much), Total score ranging from 0 (not at all) to 52 (very much), higher scores represented lower level of fatigue.
Time frame: Baseline, Week 12
Change From Baseline in the European Quality of Life - 5 Dimensions Questionnaire (EQ-5D) Scores at Week 12
EQ-5D was a participant completed instrument designed to assess impact on quality of life in terms of a single utility score in five domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems). The 5-dimensional systems are converted into a single index utility score between 0 and 1, where higher score indicated a better health state.
Time frame: Baseline, Week 12
Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to 12 weeks that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non- serious adverse events.
Time frame: Baseline up to 12 weeks
Number of Participants With Clinically Significant Laboratory Test Abnormalities
Criteria: lipids(cholesterol\[CH\] milligrams/deciliter\[mg/dL\] \>1.3\*upper limit normal(ULN), high-density lipoprotein CH mg/dL \<0.8\*lower limit normal(LLN), Low-density lipoprotein CH mg/dL \>1.2\* ULN, triglycerides mg/dL \>1.3\*ULN); neutrophil count(NC) \<1000 cells/cubic milliliters(mm\^3), platelet counts(PC) \<100,000 P/mm\^3, lymphocyte counts(LC) \<500 L/mm\^3, any single (aspartate transaminase elevation(ASTE)/alanine transaminase elevation(ALTE) \>=3\*ULN, hemoglobin(Hb) value \<8.0 grams(g)/dL or \>=2 g/dL below baseline, any serum creatinine(SC) increase(inc) \>50% or inc \>0.5 mg/dL over the average of screening(OAS) and baseline values(BV), 2 sequential ASTE/ALTE\>=3\*ULN with total bilirubin value(TBV) \>=2\*ULN, ASTE/ALTE \>=3\*ULN, ASTE/ALTE \>=5\*ULN, Hb \<8.0 g/dL or decrease of \>30% from BV, PC \<75,000 P/mm\^3, NC \<1000 cells/mm\^3, LC \<500 L/mm\^3, confirmed inc in SC \>50% OAS and BV and detection of hepatitis B virus-deoxyribonucleic acid(HBV-DNA) by the two sequential quantitative tests.
Time frame: Baseline up to 12 weeks
| Milestone | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Started | 104 | 105 |
| Completed | 100 | 95 |
| Not completed | 4 | 10 |
| Withdrew: Medication error | 1 | 0 |
| Withdrew: Insufficient clinical response | 0 | 1 |
| Withdrew: Adverse event | 3 | 9 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from swollen joint count (SJC) and tender/painful joint count (TJC) using 28 joints count, CRP (milligrams per liter \[mg/L\]) and patient global assessment of disease activity on a 100 millimeter (mm) visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \[less than or equal to\] \<= 3.2 implied low disease activity and greater than (\>) 3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) less than (\<) 2.6 implied remission.
| units on a scale | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (C-Reactive Protein [CRP]) at Week 12 | -2.43 ± 0.09 | -2.85 ± 0.09 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (millimeters per hour \[mm/hr\]) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission.
| units on a scale | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Change From Baseline in Disease Activity Score in 28 Joints Using 4 Variables (DAS28-4) (Erythrocyte Sedimentation Rate [ESR]) at Week 12 | -2.50 ± 0.09 | -2.86 ± 0.09 |
Participants with 20% improvement in 68-tender and 66-swollen joint counts and 20% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Number of Participants Achieving an American College of Rheumatology 20 Percent [%] (ACR20) Response at Week 12 | 87 | 83 |
Participants with 50% improvement in 68-tender and 66-swollen joint counts and 50% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Number of Participants Achieving an American College of Rheumatology 50% (ACR50) Response at Week 12 | 70 | 71 |
Participants with 70% improvement in 68-tender and 66-swollen joint counts and 70% improvement in at least 3 of the 5 measures: patient's global assessment of arthritis, physician global assessment of arthritis, patient's assessment of arthritis pain, health assessment questionnaire-disability index(HAQ-DI) and CRP. Patient's global assessment of arthritis: participant assessed arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Physician global assessment of arthritis: physician judged participants arthritis by 100 mm VAS, score: 0 mm (no arthritis) to 100 mm (extreme arthritis), higher score implied more arthritis. Patient's assessment of arthritis pain: participant assessed arthritis pain by 100 mm VAS, score: 0 mm (no pain) to 100 mm (most severe pain), higher score implied more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score implied more disability.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Number of Participants Achieving an American College of Rheumatology 70% (ACR70) Response at Week 12 | 32 | 48 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. Number of participants with DAS remission (DAS28-4-CRP\<2.6) were reported in this outcome measure.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Number of Participants With DAS Remission (DAS28-4-CRP <2.6) at Week 12 | 52 | 72 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<= 3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. Number of participants with DAS remission (DAS28-4-ESR\<2.6) were reported in this outcome measure.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Number of Participants With DAS Remission (DAS28-4-ESR <2.6) at Week 12 | 18 | 36 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (CRP) was calculated from SJC and TJC using 28 joints count, CRP (mg/L) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (CRP) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (CRP) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (CRP) \<2.6 implied remission. Number of participants with low disease activity (DAS28-4-CRP\<=3.2) were reported in this outcome measure.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Number of Participants With Low Disease Activity (DAS28-4-CRP <=3.2) at Week 12 | 76 | 82 |
DAS28 is a measure of disease activity in participants with rheumatoid arthritis. DAS28-4 (ESR) was calculated from SJC and TJC using 28 joints count, ESR (mm/hr) and patient global assessment of disease activity on a 100 mm visual analog scale (VAS: scores ranging from 0 mm \[very well\] to 100 mm \[extremely bad\], higher scores indicate worse health condition). Total DAS28-4 (ESR) score range: 0 (none) to 9.4 (extreme disease activity), higher score indicated more disease activity. DAS28-4 (ESR) \<=3.2 implied low disease activity and \>3.2 to \<=5.1 implied moderate disease activity, \>5.1 implied high disease activity, and DAS28-4 (ESR) \<2.6 implied remission. Number of participants with low disease activity (DAS28-4-ESR\<=3.2) were reported in this outcome measure.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Number of Participants With Low Disease Activity (DAS28-4-ESR <=3.2) at Week 12 | 44 | 63 |
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities over past week. Each activity category consisted of 2-3 items. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.
| units on a scale | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12 | -0.44 ± 0.04 | -0.46 ± 0.04 |
HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities over past week. Each activity category consisted of 2-3 items. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities. Number of participants with an improvement of at least 0.22 units in HAQ scores from baseline to Week 12 were reported in this outcome measure.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Number of Participants Achieving an Improvement of at Least 0.22 Units in Health Assessment Questionnaire (HAQ Scores) at Week 12 | 65 | 60 |
SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were aggregated to derive the two component scores (physical component scores \[PCS\], mental component scores \[MCS\]) ranging from 0 (worst) to 100 (best), where higher scores indicated good health condition.
| units on a scale | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Physical Functioning | 5.54 ± 0.67 | 6.29 ± 0.68 |
| Role Physical | 6.51 ± 0.81 | 6.97 ± 0.83 |
| Bodily Pain | 9.41 ± 0.77 | 11.92 ± 0.78 |
| General Health | 4.53 ± 0.52 | 4.72 ± 0.53 |
| Vitality | 8.07 ± 0.75 | 8.20 ± 0.76 |
| Social Function | 4.26 ± 0.63 | 5.06 ± 0.64 |
| Role Emotional | 7.23 ± 0.86 | 6.56 ± 0.87 |
| Mental Health | 4.46 ± 0.80 | 5.26 ± 0.81 |
SF-36 is a participant reported standardized survey designed to assess generic health related quality of life. It consisted of 36 items evaluating 8 aspects of functional health and well-being: physical functioning, role physical, bodily pain, social functioning, mental health, role emotional, vitality, and general health. The score range for each of the 8 health aspects was from 0 (poor health) to 100 (better health), higher scores indicating good health condition. Scores of 8 health aspects were aggregated to derive the two component scores PCS and MCS ranging from 0 (worst) to 100 (best), where higher scores indicated good health condition.
| units on a scale | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| PCS | 6.59 ± 0.58 | 7.85 ± 0.59 |
| MCS | 5.29 ± 0.76 | 5.08 ± 0.77 |
The FACIT-Fatigue Scale was a participant completed questionnaire consisted of 13 items that assessed fatigue. Each item was scored on a scale of 0 (not at all) to 4 (very much), Total score ranging from 0 (not at all) to 52 (very much), higher scores represented lower level of fatigue.
| units on a scale | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Scores at Week 12 | 5.28 ± 0.66 | 6.12 ± 0.67 |
EQ-5D was a participant completed instrument designed to assess impact on quality of life in terms of a single utility score in five domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with 3 possible answers for each item (1=no problem, 2=moderate problems, 3=severe problems). The 5-dimensional systems are converted into a single index utility score between 0 and 1, where higher score indicated a better health state.
| units on a scale | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Change From Baseline in the European Quality of Life - 5 Dimensions Questionnaire (EQ-5D) Scores at Week 12 | 0.20 ± 0.02 | 0.25 ± 0.02 |
An Adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events between first dose of study drug and up to 12 weeks that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non- serious adverse events.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| AEs | 55 | 54 |
| SAEs | 5 | 4 |
Criteria: lipids(cholesterol\[CH\] milligrams/deciliter\[mg/dL\] \>1.3\*upper limit normal(ULN), high-density lipoprotein CH mg/dL \<0.8\*lower limit normal(LLN), Low-density lipoprotein CH mg/dL \>1.2\* ULN, triglycerides mg/dL \>1.3\*ULN); neutrophil count(NC) \<1000 cells/cubic milliliters(mm\^3), platelet counts(PC) \<100,000 P/mm\^3, lymphocyte counts(LC) \<500 L/mm\^3, any single (aspartate transaminase elevation(ASTE)/alanine transaminase elevation(ALTE) \>=3\*ULN, hemoglobin(Hb) value \<8.0 grams(g)/dL or \>=2 g/dL below baseline, any serum creatinine(SC) increase(inc) \>50% or inc \>0.5 mg/dL over the average of screening(OAS) and baseline values(BV), 2 sequential ASTE/ALTE\>=3\*ULN with total bilirubin value(TBV) \>=2\*ULN, ASTE/ALTE \>=3\*ULN, ASTE/ALTE \>=5\*ULN, Hb \<8.0 g/dL or decrease of \>30% from BV, PC \<75,000 P/mm\^3, NC \<1000 cells/mm\^3, LC \<500 L/mm\^3, confirmed inc in SC \>50% OAS and BV and detection of hepatitis B virus-deoxyribonucleic acid(HBV-DNA) by the two sequential quantitative tests.
| participants | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Cholesterol | 11 | 8 |
| High-density lipoprotein Cholesterol | 1 | 1 |
| Low-density lipoprotein Cholesterol | 22 | 21 |
| Triglycerides | 6 | 10 |
| Neutrophil counts <1000 cells/mm3 | 0 | 0 |
| Platelet counts <100,000 platelets/mm3 | 0 | 0 |
| Lymphocyte counts <500 lymphocytes/mm3 | 1 | 0 |
| Any single AST and/or ALT elevation >=3xULN | 1 | 0 |
| Any single Hb value <8.0 g/dL or >=2 gm/dL | 0 | 2 |
| Any serum creatinine increase >50% | 0 | 0 |
| 2sequential AST/ALT elevations>=3xULN, TBV>=2xULN | 0 | 0 |
| 2 sequential AST or ALT elevations >=3xULN | 1 | 0 |
| 2 sequential AST or ALT elevations >=5xULN | 0 | 0 |
| 2sequential Hb<8.0 g/dL or decrease of >30%from BV | 0 | 1 |
| 2 sequential platelet counts <75,000 platelets/mm3 | 0 | 0 |
| 2 sequential neutrophil counts <1000 cells/mm3 | 0 | 0 |
| 2 sequential lymphocyte count <500 lymphocytes/mm3 | 0 | 0 |
| Confirmed increases in serum creatinine >50% | 0 | 0 |
| Detection of HBV-DNA | 0 | 0 |
Collected over From baseline up to 12 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib Modified Release (MR) | 0/104 (0%) | 5/104 (4.8%) | 10/104 (9.6%) |
| Tofacitinib Immediate Release (IR) | 0/105 (0%) | 4/105 (3.8%) | 13/105 (12.4%) |
| Event | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| Pneumocystis jirovecii pneumoniaInfections and infestations | 2/104 | 1/105 |
| PneumoniaInfections and infestations | 1/104 | 1/105 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/104 | 0/105 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/104 | 0/105 |
| AnaemiaBlood and lymphatic system disorders | 0/104 | 1/105 |
| Pneumonia bacterialInfections and infestations | 0/104 | 1/105 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 0/104 | 1/105 |
| Event | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) |
|---|---|---|
| NasopharyngitisInfections and infestations | 10/104 | 13/105 |
Full analysis set (FAS) included all participants who were randomized and received at least one dose of the randomized investigational drug.
| Age, Continuous(years) | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) | Total |
|---|---|---|---|
| Mean | 57.1 ± 11.4 | 58.9 ± 10.2 | 58 ± 10.8 |
| Sex: Female, Male(Participants) | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) | Total |
|---|---|---|---|
| Female | 86 | 75 | 161 |
| Male | 18 | 30 | 48 |
| Race/Ethnicity, Customized(Participants) | Tofacitinib Modified Release (MR) | Tofacitinib Immediate Release (IR) | Total |
|---|---|---|---|
| Asian | 104 | 105 | 209 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Ran from Nov 2014 to primary completion in Mar 2017, 27 months.
Results were first posted in Oct 2018, 1 year 6 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 27 months is above that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib